AR071311A1 - Compuesto de maleato de orvepitant cristalino anhidro (forma 1), composicion farmaceutica que lo comprende y su uso para la preparacion de un medicamento util para el tratamiento o profilaxis de enfermedades del snc - Google Patents
Compuesto de maleato de orvepitant cristalino anhidro (forma 1), composicion farmaceutica que lo comprende y su uso para la preparacion de un medicamento util para el tratamiento o profilaxis de enfermedades del sncInfo
- Publication number
- AR071311A1 AR071311A1 ARP090101268A ARP090101268A AR071311A1 AR 071311 A1 AR071311 A1 AR 071311A1 AR P090101268 A ARP090101268 A AR P090101268A AR P090101268 A ARP090101268 A AR P090101268A AR 071311 A1 AR071311 A1 AR 071311A1
- Authority
- AR
- Argentina
- Prior art keywords
- xrd
- orvepitant
- orvepitant maleate
- pattern
- kalfa
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cephalosporin Compounds (AREA)
- Liquid Crystal Substances (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compuesto de maleato de orvepitant que es maleato de orvepitant cristalino anhidro (Forma 1) que tiene el patron de difraccion de polvo de rayos X (XRD) de la Figura 1, donde el patron de XRD se expresa en términos de ángulos 2 theta y se obtiene con un difractometro usando radiacion X de cobre Kalfa. También tiene un espectro de resonancia magnética nuclear (NMR) de 13C y DSC Característicos. Composicion farmacéutica que lo comprende y su uso para la preparacion de un medicamento util para el tratamiento o profilaxis de enfermedades del Sistema Nervioso Central (SNC), como ser depresion, ansiedad, trastornos de estrés postraumático, emesis y/o trastornos del sueno. Reivindicacion 2: El compuesto de maleato de orvepitant de acuerdo con la reivindicacion 1, caracterizado adicionalmente porque proporciona un patron de difraccion de polvo de rayos X (XRD) expresado en términos de ángulos 2 theta y que se obtiene con un difractometro usando radiacion X de cobre Kalfa, donde el patron de XRD comprende picos de ángulos 2 theta esencialmente a 7,3+- 0,1, 7,5+- 0,1, 10,9+- 0,1, 12,7+- 0,1, 16,5+- 0,1 grados, que corresponden respectivamente a distancias interplanares d a 12,2, 11,8, 8,1, 7,0 y 5,4 Angstroms (A). Reivindicacion 3: El compuesto de maleato de orvepitant de acuerdo con la reivindicacion 1 o la reivindicacion 2, caracterizado adicionalmente porque proporciona un patron de XRD expresado en términos de ángulos 2 theta y que se obtiene usando radiacion X de cobre Kalfa, donde el patron de XRD comprende picos de ángulos 2 theta esencialmente en las siguientes posiciones 7,3+- 0,1, 7,5+- 0,1, 10,7+- 0,1, 10,9+- 0,1, 12,7+- 0,1, 15,0+- 0,1, 15,3+- 0,1, 16,5+- 0,1, 17,0+- 0,1, 17,5+- 0,1, 19,3+- 0,1, 19,6+- 0,1, 20,1+- 0,1, 20,3+- 0,1, 20,9+- 0,1, 21,1+- 0,1, 21,8 +- 0,1, 22,6+- 0,1 grados, que corresponden respectivamente a distancias interplanares d a 12,2, 11,8, 8,3, 8,1, 7,0, 5,9, 5,8, 5,4, 5,2, 5,1, 4,6, 4,5, 4,4, 4,4, 4,3, 4,2, 4,1, 3,9 Angstroms (A). Reivindicacion 5: El compuesto de maleato de orvepitant de acuerdo con la reivindicacion 4, caracterizado adicionalmente por que proporciona un espectro de RMN en estado solido obtenido usando un espectrometro que funciona a una frecuencia de 90,55 MHz para la observacion de 13C usando una sonda Bruker HFX MAS de 4 mm (rotacion de ángulo mágico) a una temperatura de 296K y a una velocidad de rotacion de 10 kHz, donde la RMN en estado solido comprende desplazamientos químicos a 173,6+- 0,3, 172,6+- 0,3, 165,8+- 0,3, 164,0+- 0,3, 162,6+- 0,3, 160,1+- 0,3, 146,5+- 0,3, 140,4+- 0,3, 136,5+- 0,3, 132,4+- 0,3, 131,7+- 0,3, 129,3+- 0,3, 127,6+- 0,3, 126,5+- 0,3, 121,8+- 0,3, 114,7+- 0,3, 114,2+- 0,3, 64,6+- 0,3, 57,0+- 0,3, 56,5+- 0,3, 52,8+- 0,3, 51,2+- 0.3, 48,1+- 0,3, 43,7+- 0,3, 36,6+- 0,3, 30,2+- 0,3, 24,0+- 0,3, 22,9+- 0,3, 18,7+- 0,3, 15,9+- 0,3 ppm.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0806652.4A GB0806652D0 (en) | 2008-04-11 | 2008-04-11 | Anhydrous crystal form of orvepitant maleate |
Publications (1)
Publication Number | Publication Date |
---|---|
AR071311A1 true AR071311A1 (es) | 2010-06-09 |
Family
ID=39433527
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090101268A AR071311A1 (es) | 2008-04-11 | 2009-04-08 | Compuesto de maleato de orvepitant cristalino anhidro (forma 1), composicion farmaceutica que lo comprende y su uso para la preparacion de un medicamento util para el tratamiento o profilaxis de enfermedades del snc |
Country Status (27)
Country | Link |
---|---|
US (1) | US8309553B2 (es) |
EP (1) | EP2297152B1 (es) |
JP (2) | JP5875863B2 (es) |
KR (1) | KR20110002090A (es) |
CN (1) | CN102066376B (es) |
AR (1) | AR071311A1 (es) |
AU (1) | AU2009235440B2 (es) |
BR (1) | BRPI0911678B8 (es) |
CA (1) | CA2721119C (es) |
CL (1) | CL2009000876A1 (es) |
CY (1) | CY1115961T1 (es) |
DK (1) | DK2297152T3 (es) |
EA (1) | EA017082B1 (es) |
ES (1) | ES2529295T3 (es) |
GB (1) | GB0806652D0 (es) |
HR (1) | HRP20141196T1 (es) |
IL (1) | IL208597A0 (es) |
MX (1) | MX2010011152A (es) |
PE (1) | PE20091839A1 (es) |
PL (1) | PL2297152T3 (es) |
PT (1) | PT2297152E (es) |
RS (1) | RS53732B1 (es) |
SI (1) | SI2297152T1 (es) |
TW (1) | TW201002714A (es) |
UY (1) | UY31758A (es) |
WO (1) | WO2009124996A1 (es) |
ZA (1) | ZA201007120B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101842133B (zh) * | 2007-10-30 | 2013-03-20 | 伊利克塔股份有限公司 | 放射治疗仪 |
GB0806652D0 (en) * | 2008-04-11 | 2008-05-14 | Glaxo Group Ltd | Anhydrous crystal form of orvepitant maleate |
SG11201501867UA (en) | 2012-10-11 | 2015-04-29 | Nerre Therapeutics Ltd | Novel uses |
AU2016384267B2 (en) * | 2016-01-08 | 2022-02-03 | Nerre Therapeutics Limited | Orvepitant for the treatment of chronic cough |
IL269875B2 (en) | 2017-04-10 | 2024-06-01 | Chase Therapeutics Corp | NK1 antagonist combination and a method for the treatment of synucleinopathies |
CN111032158A (zh) | 2017-06-30 | 2020-04-17 | 才思治疗公司 | 用于治疗抑郁的nk-1拮抗剂组合物和方法 |
EP4125875A1 (en) | 2020-04-03 | 2023-02-08 | NeRRe Therapeutics Limited | An nk-1 receptor antagonist for treating a disease selecting from sepsis, septic shock,, acute respiratory distress syndrome (ards) or multiple organ dysfunction syndrome (mods) |
BR112022024208A2 (pt) | 2020-06-02 | 2022-12-20 | Nerre Therapeutics Ltd | Antagonistas do receptor de neurocinina (nk)-1 para uso no tratamento de condições de fibrose pulmonar promovidas por lesão mecânica aos pulmões |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0203020D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
EP2029564A4 (en) | 2006-05-22 | 2010-01-13 | Vanda Pharmaceuticals Inc | TREATMENT OF DEPRESSIVE DISORDERS |
GB0621229D0 (en) * | 2006-10-20 | 2006-12-06 | Glaxo Group Ltd | Novel use |
WO2009059326A2 (en) * | 2007-11-02 | 2009-05-07 | Entegris, Inc. | Integral face seal |
GB0806652D0 (en) * | 2008-04-11 | 2008-05-14 | Glaxo Group Ltd | Anhydrous crystal form of orvepitant maleate |
-
2008
- 2008-04-11 GB GBGB0806652.4A patent/GB0806652D0/en not_active Ceased
-
2009
- 2009-04-08 AR ARP090101268A patent/AR071311A1/es not_active Application Discontinuation
- 2009-04-08 PE PE2009000500A patent/PE20091839A1/es not_active Application Discontinuation
- 2009-04-09 US US12/936,407 patent/US8309553B2/en active Active
- 2009-04-09 PL PL09731234T patent/PL2297152T3/pl unknown
- 2009-04-09 TW TW098111752A patent/TW201002714A/zh unknown
- 2009-04-09 RS RS20150008A patent/RS53732B1/en unknown
- 2009-04-09 ES ES09731234.2T patent/ES2529295T3/es active Active
- 2009-04-09 EP EP09731234.2A patent/EP2297152B1/en active Active
- 2009-04-09 CN CN200980122132.9A patent/CN102066376B/zh active Active
- 2009-04-09 MX MX2010011152A patent/MX2010011152A/es active IP Right Grant
- 2009-04-09 KR KR1020107025211A patent/KR20110002090A/ko active Search and Examination
- 2009-04-09 AU AU2009235440A patent/AU2009235440B2/en active Active
- 2009-04-09 WO PCT/EP2009/054295 patent/WO2009124996A1/en active Application Filing
- 2009-04-09 DK DK09731234.2T patent/DK2297152T3/da active
- 2009-04-09 CL CL2009000876A patent/CL2009000876A1/es unknown
- 2009-04-09 BR BRPI0911678A patent/BRPI0911678B8/pt active IP Right Grant
- 2009-04-09 JP JP2011503450A patent/JP5875863B2/ja active Active
- 2009-04-09 PT PT9731234T patent/PT2297152E/pt unknown
- 2009-04-09 SI SI200931110T patent/SI2297152T1/sl unknown
- 2009-04-09 CA CA2721119A patent/CA2721119C/en active Active
- 2009-04-09 EA EA201071183A patent/EA017082B1/ru not_active IP Right Cessation
- 2009-04-13 UY UY0001031758A patent/UY31758A/es not_active Application Discontinuation
-
2010
- 2010-10-06 ZA ZA2010/07120A patent/ZA201007120B/en unknown
- 2010-10-10 IL IL208597A patent/IL208597A0/en active IP Right Grant
-
2014
- 2014-06-09 JP JP2014118775A patent/JP2014205688A/ja active Pending
- 2014-12-10 HR HRP20141196AT patent/HRP20141196T1/hr unknown
-
2015
- 2015-01-29 CY CY20151100093T patent/CY1115961T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR071311A1 (es) | Compuesto de maleato de orvepitant cristalino anhidro (forma 1), composicion farmaceutica que lo comprende y su uso para la preparacion de un medicamento util para el tratamiento o profilaxis de enfermedades del snc | |
JP2012176975A5 (es) | ||
JP2018520205A5 (es) | ||
RU2599785C3 (ru) | Кристаллические формы 5-хлор-n2-(2-изопропокси-5-метил-4-пиперидин-4-ил-фенил)-n4-[2-(пропан-2-сульфонил)-фенил]-пиримидин-2,4-диамина | |
CA2776342C (en) | Agomelatine and pharmaceutical compositions thereof | |
KR20180022660A (ko) | 고체 형태 | |
WO2018027062A1 (en) | Boron-containing compounds | |
AR055567A1 (es) | Formas de crital de un derivado de imidazol y composicion farmaceutica | |
FI3694863T3 (fi) | Lorlatinibin vapaan emäksen hydraatin kidemuoto | |
RU2009133262A (ru) | Нападизилатная соль антагониста мускаринового мз-рецептора | |
JP2015522589A5 (es) | ||
JP2015522037A5 (es) | ||
HRP20150356T1 (hr) | Kristalni oblici soli prasugrela | |
JP2013503134A5 (es) | ||
JP2016505498A5 (es) | ||
Vedeanu et al. | IR and ESR investigations on V2O5–P2O5–BaO glass system with opto-electronic potential | |
Gao et al. | Synthesis and Biological Evaluation of N‐Substituted Sophocarpinic Acid Derivatives as Coxsackievirus B3 Inhibitors | |
Mohaqeq et al. | A flexible one-pot synthesis of 8, 10-dimethyl-12-aryl-9 H-naphto [1′, 2′: 5, 6] pyrano [2, 3-d] pyrimidine-9, 11-diones catalyzed by ZnO nanoparticles under solvent-free conditions | |
JP2007513907A5 (es) | ||
Yusuf et al. | Synthesis of some alkoxy based bisthiadiazolines | |
Sathe et al. | Synthesis, characterization, and antioxidant activity of thymol-based paracetamol analogues | |
AR062204A1 (es) | Formas solidas de (3'-clorobifeni-4-il)(1-pirimidin-2-il)piperidin-4-il)metanona, un metodo de preparacion, una dosificacion farmaceutica que la comprende y su uso en eltratamiento de trastornos cognitivos y de la enfermedad de alzheimer. | |
AR088359A1 (es) | FORMAS POLIMORFICAS DEL (1,1-DIOXO-l-4-TIOMORFOLINIL)-{6-[3-(4-FLUOROFENIL)-5-METIL-ISOXAZOL-4-ILMETOXI]-PIRIDIN-3-IL}-METANONA Y SU USO EN EL TRATAMIENTO DE TRASTORNOS NEUROLOGICOS | |
Hosny et al. | Anti-inflammatory activity of (2 E, 15 E)-2-[1-(2-aminophenyl) ethylidineamino]-N′-[1-(2-aminophenyl) ethylidene] benzoic acid hydrazide (AEBH) and some of its nanoparticles rare earth complexes | |
KR102640775B1 (ko) | 포스네투피탄트의 결정질 형태 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |